Teri Loxam

Ms. Loxam is an accomplished professional with over 20 years of diverse experience across investor relations, strategy, communications and finance. Ms. Loxam currently serves as Chief Operating Officer and Chief Financial Officer at Kira Pharmaceuticals, a clinical-stage biotech company developing transformative therapies for people with complement-mediated diseases. Prior to Kira, Ms. Loxam served as CFO of SQZ Biotechnologies, a novel cell therapy company developing treatments for cancer, infectious disease and other serious conditions. While at SQZ she was instrumental in raising more than $200M, including taking the company public in October 2020. Before joining SQZ Biotechnologies, Ms. Loxam served as Senior Vice President of Investor Relations and Global Communications at Merck where she helped establish the company’s leadership in immuno-oncology with the investment community along with leading internal and external communications efforts globally, which included Merck’s portfolio of therapeutics and vaccines. Previously, she was Vice President, Investor Relations for IMAX Corporation, where she helped lead the company’s IPO on the Hong Kong Exchange. Ms. Loxam also spent over a decade at Bristol-Myers Squibb in a variety of roles of increasing responsibility across strategy, treasury and investor relations. Ms. Loxam started her career as a marine biologist and worked at Sea World of San Diego for several years before making a transition into business. She has a BS in Biology from the University of Victoria, BC Canada and an MBA from the University of California, Irvine.